At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 41 enrolled
Drug / intervention
Cannabidiol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Cannabinoid Receptor Antagonist Treatment of Cognitive Dysfunction in Schizophrenia
In Brief
A Phase 2 clinical trial evaluating Cannabidiol and Placebo for Schizophrenia and Schizoaffective Disorder. Completed, enrolled 41 participants across 1 site.
Detailed Summary
This study is a six-week, randomized, placebo-controlled, fixed dose trial comparing cannabidiol Vs. placebo added to a stable dose of antipsychotic medications in patients diagnosed with schizophrenia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Schizoaffective Disorder
CountriesUnited States
CollaboratorsStanley Medical Research Institute
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 2008
Enrollment StartFeb 2009
Primary CompletionDec 2013
TodayJul 2026
First PostedJan 9, 2008
Enrollment StartFeb 1, 2009
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 18.5 years ago
Interventions
Cannabidioldrug
Active Cannabidiol daily over 6 weeks
Placebodrug
Placebo